260 related articles for article (PubMed ID: 33003418)
1. Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.
Bera TK
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003418
[TBL] [Abstract][Full Text] [Related]
2. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models.
Shancer Z; Liu XF; Nagata S; Zhou Q; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4592-4598. PubMed ID: 30782819
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.
Shancer Z; Williams M; Igelman A; Nagata S; Ise T; Pastan I; Bera TK
Antib Ther; 2018 Jun; 1(1):19-25. PubMed ID: 30272049
[TBL] [Abstract][Full Text] [Related]
4. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
5. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
6. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Tai YT; Mayes PA; Acharya C; Zhong MY; Cea M; Cagnetta A; Craigen J; Yates J; Gliddon L; Fieles W; Hoang B; Tunstead J; Christie AL; Kung AL; Richardson P; Munshi NC; Anderson KC
Blood; 2014 May; 123(20):3128-38. PubMed ID: 24569262
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
8. Engineering more efficacious antibody therapy for myeloma.
van Rhee F
Blood; 2014 May; 123(20):3062-3. PubMed ID: 24832938
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L; Cho SF; Xing L; Wen K; Li Y; Yu T; Hsieh PA; Chen H; Kurtoglu M; Zhang Y; Andrew Stewart C; Munshi N; Anderson KC; Tai YT
Leukemia; 2021 Mar; 35(3):752-763. PubMed ID: 32632095
[TBL] [Abstract][Full Text] [Related]
10. Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.
Oden F; Marino SF; Brand J; Scheu S; Kriegel C; Olal D; Takvorian A; Westermann J; Yilmaz B; Hinz M; Daumke O; Höpken UE; Müller G; Lipp M
Mol Oncol; 2015 Aug; 9(7):1348-58. PubMed ID: 25953704
[TBL] [Abstract][Full Text] [Related]
11. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
12. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
Fang Y; Hou J
Mil Med Res; 2021 Jan; 8(1):9. PubMed ID: 33504363
[TBL] [Abstract][Full Text] [Related]
14. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
[TBL] [Abstract][Full Text] [Related]
15. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
[TBL] [Abstract][Full Text] [Related]
16. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
17. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR
Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients.
Bera TK; Abe Y; Ise T; Oberle A; Gallardo D; Liu XF; Nagata S; Binder M; Pastan I
Leukemia; 2018 Feb; 32(2):569-572. PubMed ID: 29149102
[No Abstract] [Full Text] [Related]
19. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
